For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a $753 million hit for abandoning one of the drugs from that ...

AstraZeneca has agreed to buy U.S. Alexion Pharmaceuticals for $39 billion, betting on rare diseases and immunology as the British drug company emerges as one of the leading developers of a COVID ...

AstraZeneca has identified a shortcut to prominence in the genomic medicine space. Working through its Alexion rare disease unit, the Big Pharma has struck a deal to snap up struggling LogicBio ...

Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, ... Alexion plans to close the deal in four to six weeks, ...

AstraZeneca hailed its deal with Alexion as part of a strong pipeline to profitability. Photo: PA · Roland Magnusson via Getty Images AstraZeneca's (AZN.L) shares fell more than 1% in early trade in ...

UK-based AstraZeneca said it wrapped up its $39 billion acquisition of Alexion on Wednesday, a week after clearing its final hurdle with a green light from UK regulators.

AstraZeneca (NASDAQ: AZN) hopes to soon close its planned acquisition of Alexion Pharmaceuticals (NASDAQ: ALXN). The only hurdle left to jump is obtaining approval from United Kingdom regulators.

AstraZeneca (AZN-0.67%) hopes to soon close its planned acquisition of Alexion Pharmaceuticals . The only hurdle left to jump is obtaining approval from United Kingdom regulators.

- AstraZeneca's $39 billion buyout of U.S.-based rare diseases business Alexion is expected to close next week as Britain's competition watchdog cleared the deal on Wednesday. The merger, which ...

AstraZeneca's $39 billion buyout of US-based rare diseases business Alexion is expected to close next week as Britain's competition watchdog cleared the deal today.

AstraZeneca’s £28.2bn deal to buy Alexion given all-clear The CMA said it had decided not to refer the acquisition for an in-depth investigation, paving the way the deal to close on July 21.